Free Trial
NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Price, News & Analysis

Lantern Pharma logo
$4.99 -0.15 (-2.92%)
Closing price 04:00 PM Eastern
Extended Trading
$5.02 +0.03 (+0.52%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lantern Pharma Stock (NASDAQ:LTRN)

Key Stats

Today's Range
$4.85
$5.28
50-Day Range
$3.01
$5.32
52-Week Range
$2.55
$6.12
Volume
241,971 shs
Average Volume
405,484 shs
Market Capitalization
$53.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Buy

Company Overview

Lantern Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

LTRN MarketRank™: 

Lantern Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 591st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lantern Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lantern Pharma has received no research coverage in the past 90 days.

  • Read more about Lantern Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Lantern Pharma are expected to grow in the coming year, from ($1.90) to ($1.86) per share.

  • Price to Book Value per Share Ratio

    Lantern Pharma has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lantern Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    6.73% of the float of Lantern Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantern Pharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lantern Pharma has recently increased by 109.46%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lantern Pharma does not currently pay a dividend.

  • Dividend Growth

    Lantern Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.73% of the float of Lantern Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantern Pharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lantern Pharma has recently increased by 109.46%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lantern Pharma has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Lantern Pharma this week, compared to 1 article on an average week.
  • Search Interest

    11 people have searched for LTRN on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lantern Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,000,580.00 in company stock.

  • Percentage Held by Insiders

    Only 7.31% of the stock of Lantern Pharma is held by insiders.

  • Percentage Held by Institutions

    Only 28.62% of the stock of Lantern Pharma is held by institutions.

  • Read more about Lantern Pharma's insider trading history.
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Stock News Headlines

Lantern Pharma (LTRN) Projected to Post Quarterly Earnings on Thursday
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
Lantern Pharma (LTRN) Gets a Buy from Lake Street
See More Headlines

LTRN Stock Analysis - Frequently Asked Questions

Lantern Pharma's stock was trading at $3.19 at the beginning of the year. Since then, LTRN shares have increased by 56.4% and is now trading at $4.99.

Lantern Pharma Inc. (NASDAQ:LTRN) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.07.
Read the conference call transcript
.

Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Lantern Pharma's top institutional investors include Westside Investment Management Inc. (0.33%). Insiders that own company stock include Leslie W Kreis and Aaron GL Fletcher.
View institutional ownership trends
.

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO).

Company Calendar

Last Earnings
5/15/2025
Today
8/07/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LTRN
CIK
1763950
Fax
N/A
Employees
20
Year Founded
2013

Price Target and Rating

High Price Target
$25.00
Low Price Target
$25.00
Potential Upside/Downside
+401.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-83.26%
Return on Assets
-70.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.86
Quick Ratio
4.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.96 per share
Price / Book
2.55

Miscellaneous

Outstanding Shares
10,780,000
Free Float
9,997,000
Market Cap
$53.79 million
Optionable
Optionable
Beta
1.60

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:LTRN) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners